PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
27241169-8	2016	Combined treatment with hypericin and YM155 led to a more severe dissipation of the mitochondrial membrane potential and caused an increase in caspase-3 activation and subsequent PARP cleavage.	YM 155	38-43	caspase 3	Homo sapiens	143-152	
20517311-6	2010	The combination of YM155 and platinum compounds also induced synergistic increases both in the number of apoptotic cells and in the activity of caspase-3.	YM 155	19-24	caspase 3	Homo sapiens	144-153	
29689274-8	2018	YM155 induced increases in pro-apoptotic proteins (Bax and Bad), diminished anti-apoptotic proteins (Mcl-1, Bcl-xl, XIAP, survivin) and initiated cleavage of apoptotic marker proteins caspase 3 and PARP.	YM 155	0-5	caspase 3	Homo sapiens	184-193	
25948188-7	2015	With the increasing of YM155 concentration and prolonging of action time, the expression levels of mRNA and protein of survivin and BCL-2 decreased, while the expression levels of caspase-3, PARP, beclin1 and LC-3 increased.	YM 155	23-28	caspase 3	Homo sapiens	180-189	
26118775-3	2015	YM155 induced apoptosis through activation of intrinsic and extrinsic pathways that also culminated in caspase-3 activity and PARP cleavage.	YM 155	0-5	caspase 3	Homo sapiens	103-112	
26081496-4	2015	It was found that YM155 inhibited cell proliferation, colony formation, migration and invasion, induced cell apoptosis, as well as increased caspase-3, -8 and -9 activity in the OS cell lines in a dose-dependent manner.	YM 155	18-23	caspase 3	Homo sapiens	141-161	
25948188-8	2015	Compared with the YM155 group, the protein levels of LC-3 and caspase-3 were lower in YM155 combined with 3-MA group.	YM 155	18-23	caspase 3	Homo sapiens	62-71	
25220225-5	2015	The ER(-) /HER2(+) SK-BR-3 breast cancer cells and the triple-negative/caspase-3-expressing metastatic aggressive MDA-MB-231 breast cancer cells were also sensitive to YM155 with IC50 values in the low nanomolar range.	YM 155	168-173	caspase 3	Homo sapiens	71-80	
25220225-8	2015	CONCLUSIONS AND IMPLICATIONS: YM155 is a potent survivin inhibitor that has potential for the management of various breast cancer subtypes regardless of the expression of ER, HER2 and caspase-3.	YM 155	30-35	caspase 3	Homo sapiens	184-193	
24432379-3	2013	The combination of YM155 with docetaxel showed synergistic antiproliferative and caspase 3/7-inducing effects in MRK-nu-1 and MDA-MB-453 human TNBC cell lines in vitro.	YM 155	19-24	caspase 3	Homo sapiens	81-90	
23618862-6	2013	Treatment of HL-60 and U937 cells with YM155 induced apoptosis concomitant with the activation of caspase-8 and caspase-3.	YM 155	39-44	caspase 3	Homo sapiens	112-121	
23618862-8	2013	When cells were pretreated with Z-IETD-FMK, the activation of caspase-3 was completely abolished, suggesting that caspase-8 may be involved in the activation of caspase-3 during YM155-induced apoptosis.	YM 155	178-183	caspase 3	Homo sapiens	62-71	
23618862-8	2013	When cells were pretreated with Z-IETD-FMK, the activation of caspase-3 was completely abolished, suggesting that caspase-8 may be involved in the activation of caspase-3 during YM155-induced apoptosis.	YM 155	178-183	caspase 3	Homo sapiens	161-170	
23267699-10	2012	Annexin V assay, cell cycle, and activation of caspase-3 demonstrates that YM155 induced apoptosis in SK-NEP-1 cells.	YM 155	75-80	caspase 3	Homo sapiens	47-56